Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily pill help restore skin color in vitiligo?

NCT ID NCT06113445

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times

Summary

This phase 3 trial tests an oral drug called povorcitinib in about 467 adults with nonsegmental vitiligo, a condition causing white patches on the skin. Participants take the drug or a placebo daily for 52 weeks to see if it safely improves skin color on the face and body. The goal is to find a new treatment option for this long-term skin condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Povorcitinib (oral tablet)
What this could lead to
If it works, this could offer a new daily pill to help restore skin color in people with vitiligo, reducing visible patches.
What could go wrong
This is a phase 3 trial, but results are not yet available. The drug may not work for everyone, and side effects are possible. It requires ongoing treatment, not a one-time fix.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

467 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥ 18 years. * Clinical diagnosis of nonsegmental vitiligo and meet the following: * T-BSA ≥ 5% * T-VASI score ≥ 4 * F-BSA ≥ 0.5% * F-VASI score ≥ 0.5 * Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit. * Willingness to avoid pregnancy or fathering children. Exclusion Criteria: * Other forms of vitiligo or skin depigmentation disorders. * Clinically significant abnormal TSH or free T4 at screening. * Use of laser or phototherapy within 8 weeks and dihydroxyacetone within 4 weeks prior to Day 1. * Current or past use of the depigmenting agent monobenzyl ether of hydroquinone including Benoquin®. * History of melanocyte-keratinocyte transplantation procedure or other surgical treatment for vitiligo. * Spontaneous and significant repigmentation within 6 months prior to screening. * Women who are pregnant, considering pregnancy, or breast feeding. * Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or recurrent dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies. * Evidence of infection with TB, HBV, HCV or HIV. * History of failure to JAK inhibitor treatment of any inflammatory disease. * Laboratory values outside of the protocol-defined ranges. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonsegmental vitiligo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

generalized vitiligo vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonsegmental vitiligo

Contacts and locations

Locations

  • Allcutis Research, Llc

    Beverly, Massachusetts, 01915, United States

  • Alliance Clinical Trials

    Waterloo, Ontario, N2J 1C4, Canada

  • Beldio Research Gmbh

    Memmingen, 87700, Germany

  • Bravis Ziekenhuis

    Bergen op Zoom, 4624 VT, Netherlands

  • Cahaba Dermatology

    Hoover, Alabama, 35244, United States

  • Care Clinic

    Ottawa, Ontario, K1A 0K9, Canada

  • Carpe Diem Centrum Medycyny Estetycznej

    Warsaw, 02-661, Poland

  • Center For Clinical Studies

    Houston, Texas, 77004, United States

  • Centre Hospitalier Universitaire (Chu) - Hopital Henri Mondor

    Bordeaux, 33075, France

  • Centre Hospitalier Universitaire de Bordeaux - Hopital Saint - Andre

    Bordeaux, 33075, France

  • Centre Hospitalier Universitaire de Liege - Sart Tilman

    Liège, 04000, Belgium

  • Centro de Dermatologia de Monterrey

    Monterrey, 64460, Mexico

  • Cleaver Medical Group

    Cumming, Georgia, 30040, United States

  • Clinica Universidad de Navarra (Cun)

    Madrid, 31008, Spain

  • Clinica de Enfermedades Cronicas Y de Procedimientos Especiales (Cecype)

    Morelia, 58249, Mexico

  • Clinical Research Partners Llc Crp Richmond Forest Avenue Office Building Location

    Richmond, Virginia, 23226, United States

  • Clinical Science Institute Clinical Research Specialists Inc

    Santa Monica, California, 90404, United States

  • Clinique de Courlancy

    Reims, 51100, France

  • Cliniques Universitaires Ucl Saint-Luc

    Woluwe-Saint-Lambert, 01200, Belgium

  • Cura Clinical Research

    Sherman Oaks, California, 91403, United States

  • Derm Research Center of New York Inc

    Stony Brook, New York, 11790, United States

  • Derma-Study-Center Friedrichshafen Gmbh

    Friedrichshafen, 88045, Germany

  • Dermapolis Medical Dermatology Center Dr N. Med. Edyta Gebska

    Chorzów, 41-516, Poland

  • Dermatologische Gemeinschaftspraxis Dres. Quist

    Mainz, 55128, Germany

  • Dermatology Associates of Plymouth Meeting

    Plymouth Meeting, Pennsylvania, 19462, United States

  • Dermatology Research Institute

    Calgary, Alberta, T2J 7E1, Canada

  • Dermatology Specialists of Spokane

    Spokane, Washington, 99202, United States

  • Dermatology and Surgery Specialists of North Atlanta

    Marietta, Georgia, 30068, United States

  • Dermedic Jacek Zdybski

    Ostrowiec Świętokrzyski, 27-400, Poland

  • Dermeffects

    London, Ontario, N6H 5L5, Canada

  • Dermodent Centrum Medyczne Aldona Czajkowska Rafa¿ Czajkowski

    Osielsko, 86-031, Poland

  • Dokkyo Medical University Saitama Medical Center

    Minamikoshigaya, 343-8555, Japan

  • Emc Instytut Medyczny Spolka Akcyjna-Euromedicare Szpital Specjalistyczny Z Przychodnia

    Wrocaw, 54144, Poland

  • Empire Dermatology

    East Syracuse, New York, 13057, United States

  • Encore Medical Research, Llc

    Hollywood, Florida, 33021, United States

  • Enverus Medical Research

    Surrey, British Columbia, V3V 0C6, Canada

  • Etg Warszawa

    Warsaw, 02-777, Poland

  • Forcare Clinical Research

    Tampa, Florida, 33613, United States

  • Great Lakes Research Group Inc

    Bay City, Michigan, 48706, United States

  • Grupo Clínico Catei Sc

    Providencia 5TA Seccion, Mexico

  • Hamamatsu University Hospital

    Hamamatsu, 431-3192, Japan

  • Hopital Larrey

    Toulouse, 31059, France

  • Hopital Universitaire de Bruxelles/ Academisch Ziekenhuis Burssel

    Brussel/ Brussels/bruxelles, 01070, Belgium

  • Hospital Clinic I Provincial de Barcelona

    Barcelona, 08036, Spain

  • Hospital Universitari Germans Trias I Pujol (Hugtp)

    Badalona, 08916, Spain

  • Hospital Universitario Fundacion Alcorcon

    Alcorcón, 28922, Spain

  • Hospital Universitario Ramon Y Cajal

    Madrid, 28034, Spain

  • Hospital de Manises

    Manises, 46940, Spain

  • Instituto de Investigaciones Aplicadas A La Neurociencia A.C

    Durango, 34000, Mexico

  • International Clinical Research Tennessee Llc

    Murfreesboro, Tennessee, 37130, United States

  • Jdr Dermatology Research

    Las Vegas, Nevada, 89148, United States

  • Jordan Valley Dermatology Center

    West Jordan, Utah, 84088, United States

  • Juntendo University Urayasu Hospital

    Urayasu, 279-0021, Japan

  • Klinikum Der Johann Wolfgang Goethe University

    Frankfurt am Main, 60590, Germany

  • Kobe University Hospital

    Kobe, 6500017, Japan

  • Kochi Medical School Hospital

    Nankoku, 783-8505, Japan

  • Leader Research

    Burlington, Ontario, L7R 4H9, Canada

  • Medisearch Clinical Trials

    Saint Joseph, Missouri, 64506, United States

  • Metro Boston Clinical Partners

    Brighton, Massachusetts, 02135-3511, United States

  • Nagasaki University Hospital

    Nagasaki, 852-8501, Japan

  • Nagoya City University Hospital

    Nagoya, 467-8602, Japan

  • National Hospital Organization Okayama Medical Center

    Okayama, 701-1192, Japan

  • National University Corporation - Tokyo Medical and Dental University (Tmdu)

    Tokyo, 113-8519, Japan

  • Niigata University Medical and Dental Hospital

    Niigata, 9518520, Japan

  • North York Research Inc.

    North YORK, Ontario, M2M 4J5, Canada

  • Ntt Medical Center Tokyo

    Shinagawa-ku, 141-8625, Japan

  • Olympian Clinical Research

    Tampa, Florida, 33609, United States

  • Options Research Group, Llc

    Kokomo, Indiana, 46901, United States

  • Osaka University Hospital

    Suita, 565-0871, Japan

  • Panstwowy Instytut Medyczny Mswia

    Warsaw, 02-507, Poland

  • Pivotal Research Solutions

    Stonecrest, Georgia, 30038, United States

  • Progressive Clinical Research

    San Antonio, Texas, 78213, United States

  • Renaissance Research

    Cape Coral, Florida, 33991, United States

  • Revival Research Institute, Llc Dermatology

    Troy, Michigan, 48084, United States

  • Sadick Dermatology Sadick Research Group

    New York, New York, 10075, United States

  • San Marcus Research Clinic Inc.

    Miami Lakes, Florida, 33014, United States

  • Savin Medical Group, Rc

    Miami, Florida, 33156, United States

  • Siena Medical Research Corporation

    Ottawa, Ontario, K1A 0K9, Canada

  • Skin Health

    Peterborough, Ontario, K9J 5K2, Canada

  • Skin Research of South Florida, Llc

    Miami, Florida, 33173, United States

  • St. Marianna University School of Medicine Hospital

    Kawasaki, 216-8511, Japan

  • Sutter Health Palo Alto Medical Foundation Pamf Sunnyvale Center

    Sunnyvale, California, 94086, United States

  • Synexus Polska Sp Z Oo Oddzial W Czestochowie

    Częstochowa, 42-202, Poland

  • Synexus Polska Sp Z Oo Oddzial W Lodzi

    Lodz, 90-127, Poland

  • Synexus Polska Sp. Z O.O. Oddzial W Katowicach

    Katowice, 40-040, Poland

  • Synexus Polska Sp. Z O.O. Oddzial W Warszawie

    Warsaw, 02-672, Poland

  • Tohoku University Hospital

    Sendai, 980-8574, Japan

  • Tokyo Medical University Hospital

    Shinjuku-ku, 160-0023, Japan

  • Trials in Medicine S.C.

    Deleg. Cuauhtemoc, 06700, Mexico

  • Universidad Autonoma de Nuevo Leon (Uanl) - Hospital Universitario Dr. Jose Eleuterio Gonzalez - Cen

    Monterrey, 64660, Mexico

  • Universitair Ziekenhuis Gent (Uz Gent)

    Ghent, 09000, Belgium

  • Universitatsklinikum Erlangen

    Erlangen, 91054, Germany

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, 602-8566, Japan

  • University of California Irvine

    Irvine, California, 92697, United States

  • University of Texas Physicians - Bellaire Station

    Bellaire, Texas, 77401, United States

  • Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W Rzeszowie

    Rzeszów, 35-055, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, 80-214, Poland

  • Uva - Amc - Stichting Nederlands Instituut Voor Pigmentstoornissen (Snip) (Netherlands Institute For

    Amsterdam, 1105 AZ, Netherlands

  • Wayne State University Physician Group Dermatology

    Dearborn, Michigan, 48124, United States

  • Yamagata University Hospital

    Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.